
Gensight Biologics SA
PAR:SIGHT

Cash Flow Statement
Cash Flow Statement
Gensight Biologics SA
Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | |||||||||||||
Net Income |
(33)
|
(39)
|
(31)
|
(27)
|
(34)
|
(28)
|
(29)
|
(31)
|
(28)
|
(29)
|
(26)
|
(20)
|
|
Depreciation & Amortization |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
|
Other Non-Cash Items |
3
|
2
|
2
|
3
|
12
|
13
|
6
|
(0)
|
(3)
|
(6)
|
(3)
|
1
|
|
Cash Interest Paid |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
2
|
0
|
0
|
|
Change in Working Capital |
2
|
2
|
(0)
|
8
|
6
|
(5)
|
5
|
7
|
(4)
|
0
|
2
|
1
|
|
Cash from Operating Activities |
(28)
N/A
|
(35)
-23%
|
(28)
+19%
|
(15)
+45%
|
(15)
+2%
|
(19)
-23%
|
(17)
+8%
|
(24)
-38%
|
(34)
-43%
|
(33)
+1%
|
(25)
+26%
|
(16)
+36%
|
|
Investing Cash Flow | |||||||||||||
Capital Expenditures |
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Other Items |
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cash from Investing Activities |
(1)
N/A
|
(0)
+71%
|
(0)
+46%
|
(0)
-145%
|
(0)
-50%
|
(0)
+76%
|
(0)
+82%
|
(0)
-963%
|
0
N/A
|
0
+34%
|
0
-9%
|
0
-66%
|
|
Financing Cash Flow | |||||||||||||
Net Issuance of Common Stock |
(0)
|
8
|
16
|
9
|
24
|
52
|
28
|
(0)
|
(0)
|
0
|
4
|
16
|
|
Net Issuance of Debt |
0
|
(0)
|
5
|
10
|
11
|
5
|
(4)
|
(5)
|
2
|
11
|
12
|
5
|
|
Other |
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(0)
|
(0)
|
|
Cash from Financing Activities |
(0)
N/A
|
8
N/A
|
21
+181%
|
18
-14%
|
34
+86%
|
56
+65%
|
24
-58%
|
(6)
N/A
|
0
N/A
|
10
+10 184%
|
16
+62%
|
22
+36%
|
|
Change in Cash | |||||||||||||
Effect of Foreign Exchange Rates |
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
|
Net Change in Cash |
(29)
N/A
|
(27)
+6%
|
(7)
+74%
|
3
N/A
|
19
+622%
|
37
+100%
|
6
-83%
|
(30)
N/A
|
(34)
-12%
|
(23)
+31%
|
(8)
+63%
|
6
N/A
|
|
Free Cash Flow | |||||||||||||
Free Cash Flow |
(29)
N/A
|
(35)
-20%
|
(28)
+19%
|
(15)
+45%
|
(15)
+2%
|
(19)
-23%
|
(17)
+7%
|
(24)
-38%
|
(34)
-43%
|
(33)
+2%
|
(25)
+26%
|
(16)
+36%
|